Doramapimod (BIRB 796)

For research use only. Not for use in humans.

目录号:S1574 中文名称:达马莫德

Doramapimod (BIRB 796) Chemical Structure

CAS No. 285983-48-4

Doramapimod (BIRB 796)是一种泛p38 MAPK抑制剂,在无细胞试验中作用于p38α/β/γ/δ的IC50分别为38 nM,65 nM,200 nM 和520 nM,并且能够与p38α结合,在THP-1细胞中Kd为0.1 nM,比作用于JNK2选择性高330倍,对c-RAF,Fyn 和Lck具有较弱的抑制作用,对ERK-1,SYK,IKK2也有微弱抑制作用。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2403.35 现货
RMB 1221.86 现货
RMB 2215.96 现货
RMB 3866.11 现货
RMB 12039.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Doramapimod (BIRB 796)发表文献91篇:

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述 Doramapimod (BIRB 796)是一种泛p38 MAPK抑制剂,在无细胞试验中作用于p38α/β/γ/δ的IC50分别为38 nM,65 nM,200 nM 和520 nM,并且能够与p38α结合,在THP-1细胞中Kd为0.1 nM,比作用于JNK2选择性高330倍,对c-RAF,Fyn 和Lck具有较弱的抑制作用,对ERK-1,SYK,IKK2也有微弱抑制作用。
特性 BIRB 796是第一个进入三期临床试验的p38 MAPK抑制剂。
靶点
JNK2 [1]
()
c-RAF [1]
()
Fyn [1]
()
p38α [1]
(Cell-free assay)
p38α [7]
()
0.1 nM(Kd) 38 nM
体外研究

BIRB 796作用于ERK-1,SYK,IKK2β,ZAP-70,EGFR激酶,HER2,蛋白激酶 A(PKA),PKC,PKC-α,PKC-β(I和II)和PKC-γ没有明显抑制效果。BIRB 796通过在吗啉氧和p38α的ATP结合域间形成氢键,显著提高亲和力。BIRB 796是作用于人类p38 MAPK的最有效和分离最慢的抑制剂之一。[1] BIRB 796 有效抑制c-Raf-1和Jnk2α2,IC50分别为1.4和0.1 nM。[2] 高浓度BIRB796也抑制SAPK3/p38γ的活性和激活。BIRB796阻断压力诱导的框架蛋白SAP97磷酸化, SAP97是SAPK3/p38γ的底物。BIRB796作用于HEK293细胞,阻断JNK1/2激活和活性,而作用于Hela细胞,不抑制ERK1/ERK2激活和活性。而且, BIRB796与p38 MAPKs或JNK1/2的结合,降低上游激酶MKK6或MKK4磷酸化,而不增强去磷酸化。 [3] BIRB 796 作用于TNF-α和TGF-β1引起的BMSCs,下调IL-6和VEGF分泌。[4] BIRB-796有吡唑环 ,使亲脂的末端异丁基基团 与低选择性位点结合,甲苯基环与高选择性位点结合。BIRB-796也抑制B-Raf和Abl,IC50分别为83 nM 和14.6 μM。 [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-92 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISyVZVKSzVyPUK0MlM5OzhizszN M{DuU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-H2228 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rjVGlEPTB;MkOuOlY3QCEQvF2= M{jZR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
CAPAN-1 M3XxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnnc2Y6UUN3ME2yNk4yQDh2IN88US=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
SK-MEL-1 NYXrenFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWxVpp[UUN3ME2yNE4{Pjh|IN88US=> Ml3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
DB M3X6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTSTWM2OD1zOD63PVI{KM7:TR?= NXTZPYlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
AN3-CA MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T5W2lEPTB;MUiuNUDPxE1? NVzC[pV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
EW-13 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDZXHVKSzVyPUG3Mlk2OTZizszN NHjlVo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
LC-2-ad MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37WRWlEPTB;MUeuOFM3PiEQvF2= M3jRU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
ES8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;reopKSzVyPUG3MlE3PyEQvF2= Mn7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-H1581 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTFTWM2OD1zNz6wOFQ4KM7:TR?= M1nQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HMV-II MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljETWM2OD1zND6yN|A6KM7:TR?= Mn76QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
BEN MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LuUGlEPTB;MUOuNVI3PCEQvF2= NEDZRZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NBsusSR MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nqeGlEPTB;MUCuPFI{PSEQvF2= NE\lcJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
MS-1 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTmR3pKSzVyPUGwMlgzOzVizszN MkHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
BFTC-905 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHySZJKSzVyPUGwMlEzOzNizszN MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-SNU-1 M3Oz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGyZYdKSzVyPUmuNFY4OzlizszN MoexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
MPP-89 NULaV4syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRThwNE[yOVEh|ryP MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
T-24 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwNEC2O|Mh|ryP NWfaTpo5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
KP-N-YN NULxV41yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzkOFVyUUN3ME24MlIxOTlizszN MoPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
IST-MES1 NVLJWph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD0TJR5UUN3ME23Mlk2PjN5IN88US=> NYi0VGYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-H358 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTdwNUO4JO69VQ>? MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
GOTO NGrwOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXc|JJUUN3ME22MlM6OTZzIN88US=> NGnPdY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
DU-145 NGjYT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDCTWM2OD1|LkmzPFEyKM7:TR?= NU\Pb5Z3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
EoL-1-cell NEXqbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPZTWM2OD1yLkO0O|Y{KM7:TR?= NHnybmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KYSE-270 M2Lv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP5TWM2OD1{ND61OVc{KM7:TR?= NELINYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HCC1806 NGTLSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[3Tm1KSzVyPUK0Mlc4QTlizszN NULwdW1HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HuO-3N1 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHabW5KSzVyPUK1MlgyQDVizszN MmL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HOS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXpWJFKSzVyPUK1MlkzQTJizszN MlvYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KYSE-510 M{\2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fBNWlEPTB;Mk[uNVYyOiEQvF2= M4m4OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
COLO-741 NHf0d2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlThTWM2OD1{Nj6zN|I6KM7:TR?= NYHPOHFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
H-EMC-SS NFXGbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki2TWM2OD1{Nj65NlQ2KM7:TR?= NW\xe45NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HCC1937 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL5TWM2OD1{Nz6yNlM5KM7:TR?= M1zHRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-H2126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ5LkO5O|Uh|ryP Mlq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
NCI-H1703 NWjnN5hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorGTWM2OD1{OD6wOFE{KM7:TR?= NHTS[4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
U-2-OS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfETWM2OD1{OD61OVE2KM7:TR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
DBTRG-05MG Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PjUWlEPTB;MkiuOVY2OSEQvF2= NY\CS|FQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
MHH-ES-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFThNVBKSzVyPUOxMlk1OSEQvF2= NHnveHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HCC1419 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGxTWM2OD1|Mj6xNVE6KM7:TR?= NX;hUVdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HOP-62 NILnNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN{LkK3NFEh|ryP MlrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
AM-38 MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknhTWM2OD1|Mj65PVMyKM7:TR?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-H2009 NEHVcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPGTWM2OD1|Mz60NFA4KM7:TR?= NEC4TXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
EM-2 M3rZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTETWM2OD1|Mz61OVEyKM7:TR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
SW1116 M{n5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHKTWM2OD1|ND60PFM5KM7:TR?= NIXVTpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
SK-N-AS NHjvTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDSfFJKSzVyPUO1MlA4OTRizszN NILWR2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
ChaGo-K-1 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfvTWM2OD1|NT62NFMzKM7:TR?= MmDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
RT-112 M1;kSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjzTWM2OD1|NT65PFc6KM7:TR?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HTC-C3 MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;VNZdKSzVyPUO2MlI{PTVizszN Mo[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
SK-NEP-1 NGfMe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHOcnpKSzVyPUO2MlYyODZizszN NWL1OlVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
LB831-BLC NVnSWldvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\GPI9pUUN3ME2zO{43PTRzIN88US=> MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
CTB-1 NETo[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH36UVBKSzVyPUO4MlQ2OTJizszN M3rOWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
MOLT-4 NFLZcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[wOmRKSzVyPUO4Mlg{QTFizszN MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
SW756 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP5TWM2OD12MD65N|g2KM7:TR?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
CAL-72 NXzhZ3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTR{LkCzJO69VQ>? NGL0SIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KNS-62 NHi5WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC5W5dKSzVyPUSyMlYzQTZizszN MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
KARPAS-299 NISwRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHKTWM2OD12Mz6zNlM{KM7:TR?= Mmj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HEL M2roT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTR3LkS2OFYh|ryP MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KP-4 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOwTWM2OD12Nj63N|YyKM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NEC8 NF;hfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm2TWM2OD12Nz6xOlYyKM7:TR?= NYC1fmUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
G-402 NFHwNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR6LkewNVIh|ryP MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
Sf21 MljmSpVv[3Srb36gZZN{[Xl? NUKzSG9USmmwZHnu[{Bi\m[rbnn0fUB1dyC5aXzkJJR6eGViaIXtZY4h[mmxdHnuJIxi[mWubHXkJJA{QCCjbIDoZUApQSC2bzCzOVIhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDz[lIyKGmwc3XjeEBk\WyuczDTVHIh[W6jbInzbZMtKEumIE2gNE4xODBzMkOg{txONg>? M2XrNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEO0OFMyLz5{OEizOFQ{OTxxYU6=
THP1 Mlm5SpVv[3Srb36gZZN{[Xl? M1HReGlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBqdiCqdX3hckBVUFBzIHPlcIx{NCCLQ{WwJF0hOC5yMUOg{txONg>? MmDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|MkW3OlgoRjF6M{K1O|Y5RC:jPh?=
U937 NHPIPWJCdnSraX7mcIFudWG2b4L5JIF{e2G7 M4f4OlIhcHK| NX;RdXAzSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCmaX\m[ZJmdnSrYYTl[EBpfW2jbjDVPVM4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNWmwZIXj[YQhXE6IYXzwbIEheHKxZIXjeIlwdiCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEySUz3zeIlufWyjdHnvckBnd3JiNDDodpMh[nlic3Hu[Jdq[2hiRVzJV2EhemWuYYTpeoUhfG9idnXobYNt\S22cnXheIVlKGOxboTyc4wtKEmFNUCgQUAxNjBzNTFOwG0v MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjhyMEOwPUc,OjZ6MECzNFk9N2F-
THP1 NIrQTIlHfW6ldHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIGTOSoFteGijIIDyc4R2[3Srb36gbY4hcHWvYX6gWGhROSClZXzsd{whUUN3MDC9JFAvODF6IN88UU4> MlPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl|NU[5NlkoRjF7M{W2PVI6RC:jPh?=
THP1 NEjiXIZHfW6ldHnvckBie3OjeR?= NGDFTYJKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJJR2dW:{IH7lZ5Jwe2m|IH\hZ5Rwei2jbIDoZUApXE6ILXHsdIhiMSCycn;keYN1cW:wIHnuJHRJWC1zIHPlcIx{NCCHQ{WwJF0hOC5yMUig{txONg>? MlfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJyOE[0PFUoRjF{MEi2OFg2RC:jPh?=
THP NFXJOXlHfW6ldHnvckBie3OjeR?= M3nxd3Rme3SnZDDmc5IhcW6qaXLpeIlwdiCxZjDUeY1weiCwZXPyc5NqeyCoYXP0c5ItKGGucHjhJIlvKFSKUDDj[YxteyxiRVO1NEA:KDBwMEG4JO69VS5? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDV4MUC4O{c,OTR3NkGwPFc9N2F-
THP1 MXLGeY5kfGmxbjDhd5NigQ>? Mo[zTY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDUUmZidHCqYTDwdo9lfWO2aX;uJIlvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkCxPEDPxE1w M1frVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[wNVA5Lz5zN{W2NFExQDxxYU6=
THP1 Mo\oSpVv[3Srb36gZZN{[Xl? M4XXV2lvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhXE6IYXzwbIEheHKxZIXjeIlwdiCrbjDoeY1idiCWSGCxJINmdGy|LDDJR|UxKD1iMD6wNVgh|ryPLh?= M33BdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NE[yPVQxLz5zOES2Nlk1ODxxYU6=
HLF M3vjbWZ2dmO2aX;uJIF{e2G7 MlXXTY5pcWKrdHnvckBw\iCyM{jhcJBp[SCyaH;zdIhwenmuYYTpc44hcW5iSVytNU1idHCqYT3zeIlufWyjdHXkJGhNTiClZXzsd{whUUN3MDC9JFAvODR5IN88UU4> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZyMkK2Nkc,OTh4MEKyOlI9N2F-
HLF MlHoSpVv[3Srb36gZZN{[Xl? NH3oSoxKdmirYnn0bY9vKG:oIFjTVFI4KHCqb4PwbI9zgWyjdHnvckBqdiCLTD2xMYFteGijLYP0bY12dGG2ZXSgTGxHKGOnbHzzMEBKSzVyIE2gNE4xPThizszNMi=> NXvVVZEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2NFIzPjJpPkG4OlAzOjZ{PD;hQi=>
HEK293F MmLrSpVv[3Srb36gZZN{[Xl? M{nhdWlvcGmkaYTpc44hd2Zic3;kbZVuKGG{c3XuZZRmKGGldHn2ZZRm\CCQLYTldo1qdmGuIFfTWE11[WepZXSgRpJ2\2mjIH3hcIF6cSCPUFuxJIV5eHKnc4Pl[EBqdiCKRVuyPVNHKGOnbHzzJJV{cW6pIF\BUU1xOzi2aXTlJIF{KHO3YoP0doF1\SCkeTDJUWFRKGG|c3H5MEBKSzVyIE2gNE4yPCEQvF2u MmjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NEGzOlIoRjJ7NUSxN|YzRC:jPh?=
BL21(DE3) M{jtNWZ2dmO2aX;uJIF{e2G7 MlXYTY5pcWKrdHnvckBw\iCyM{jhcJBp[SCjY4TpeoUh\m:{bTDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzKFTFN{kh[2WubIOgZpkhUFSURjDhd5NigSxiSVO1NEA:KDBwMkWg{txONg>? M3X2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK4PFU5Lz5zOUmyPFg2QDxxYU6=
whole blood cells NXXRVnNESW62aXnu[oxidW2jdH;yfUBie3OjeR?= MXe0JIhzew>? MUHBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIIfoc4xmKGKub3;kJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBi\nSncjC0JIhzeyCkeTD0bY1mNXKnc3;seoVlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwNjFOwG0v M2G3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{S5NlgzLz5{Mke0PVI5OjxxYU6=
A673 NF3wUWtyUFSVIHHzd4F6 NGLHb3RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NHrMRZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY NHq1[ZVyUFSVIHHzd4F6 M{fzeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| M1v6R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NVz1R5RueUiWUzDhd5NigQ>? MnjOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ M3jVfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH MojCdWhVWyCjc4PhfS=> NYLrVpVEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> M3zJZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) M1;XUJFJXFNiYYPzZZk> M2XuOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MmPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 M{HYOZFJXFNiYYPzZZk> NG\VN2xyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz M1jmVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MWPxTHRUKGG|c3H5 NHS4RlVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NG\JcZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-p38 / γ-H2AX ; 

PubMed: 27082306     


The expression of p-P38 was tested via protein gel blot after the cells were treated with BIRB796.

mTOR / p-S6K / S6K / p-MK2 / MK2 / p-Hsp27 / Hsp27 ; 

PubMed: 26844273     


CRC cells were treated with 4 μM LY2228820, 10 μM BIRB796 or 10 μM SB202190 for 2 h and p38 and mTORC1 signaling was analyzed by immunoblot.

p-p38 / p38 ; 

PubMed: 23349819     


The inhibitory effect of phosphorylated p38 in KB, KBV200 (B) and in MCF-7, MCF-7/ADR (C) treated with BIRB796 at various concentrations after 24 h. 

27082306 26844273 23349819
体内研究 BIRB 796按30 mg/kg剂量作用于LPS刺激的鼠,抑制TNF-α达84%。作用于患胶原诱导的关节炎鼠显示高效性。[1] BIRB 796口服处理给鼠,具有好的药物动力学特征。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:

[2]

- 合并
  • Animal Models: 患胶原诱导的关节炎雌性Balb/c鼠
  • Dosages: 1 mg/kg(静脉注射)或10 mg/kg(口服)
  • Administration: 静脉注射或口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (189.51 mM)
Ethanol 100 mg/mL (189.51 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 527.66
化学式

C31H37N5O3

CAS号 285983-48-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02211885 Completed Drug: 14C-BIRB 796 BS Healthy Boehringer Ingelheim October 2002 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

相关p38 MAPK产品

Tags: 购买Doramapimod (BIRB 796) | Doramapimod (BIRB 796)供应商 | 采购Doramapimod (BIRB 796) | Doramapimod (BIRB 796)价格 | Doramapimod (BIRB 796)生产 | 订购Doramapimod (BIRB 796) | Doramapimod (BIRB 796)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID